Nick Williams

Nick is a Partner at Medicxi and joined the firm in 2018.  He led Medicxi's investment in Phathom Pharmaceuticals (NASDAQ:PHAT) and currently serves on the boards of a number of portfolio companies, including Altesa Biosciences, Ethyreal Bio and Vaderis Therapeutics.

Nick's prior investments include Rapt Therapeutics (acquired by GSK), MiroBio (acquired by Gilead Sciences) and Versanis Bio (acquired by Eli Lilly).

Nick graduated with an MPharm from Cardiff University and completed his training at St George's Hospital, London before returning to Cardiff to receive his PhD in urological drug delivery.